Radiotherapy and Oncology最新文献

{"title":"Patient selection for proton therapy in lung cancer: Updating and internal-external cross-validation of a normal tissue complication probability model for acute oesophageal toxicity.","authors":"R Wijsman, J G M van Loon, R Bartels, B Stam, D A X Schinagl, L Boersma, J B Reitsma, J A Langendijk, E Schuit","doi":"10.1016/j.radonc.2026.111823","DOIUrl":"https://doi.org/10.1016/j.radonc.2026.111823","url":null,"abstract":"<p><strong>Purpose: </strong>To externally validate and update a published normal tissue complication probability (NTCP) model for the prediction of Grade ≥ 2 acute oesophageal toxicity (AOT) in lung cancer patients receiving (chemo-)radiotherapy (predictors: concurrent chemotherapy, gender, tumour stage, mean oesophagus dose (MOD)).</p><p><strong>Methods and materials: </strong>Patient cohorts from four centres were available. Initial external validation was performed by assessing model performance. Heterogeneity of performance across cohorts was evaluated using an internal-external cross validation (IECV) method. Based on the IECV procedure, parameters were added or removed from the model to lower heterogeneity in model performance across cohorts with the aim to create a model that performed uniformly well across centres. Ridge regression was used to create the final model and bootstrapping techniques were applied to perform further internal validation.</p><p><strong>Results: </strong>Out of 937 patients, 444 (47%) had Grade ≥ 2 AOT. External validation indicated model recalibration was necessary for 1 cohort and model revision for another. IECV showed heterogeneity of performance of the original model across cohorts. To lower heterogeneity in model performance, the predictors concurrent chemotherapy, gender, and tumour stage were removed from the model, and overall treatment time (OTT) was added. The final model containing MOD and OTT as predictors showed low levels of heterogeneity in model performance (I² of 0% for all performance measures) with optimism-corrected AUC of 0.75, calibration intercept of -0.01 and slope of 1.26.</p><p><strong>Conclusion: </strong>The validation and updating of an NTCP-model for AOT resulted in a prediction model performing well in varying patient cohorts. Therefore, this updated model was added to the national indication protocol to select lung cancer patients for proton radiotherapy.</p>","PeriodicalId":21041,"journal":{"name":"Radiotherapy and Oncology","volume":" ","pages":"111823"},"PeriodicalIF":5.8,"publicationDate":"2026-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149196105","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Uncertainty quantification for detecting out-of-distribution cases in deep learning segmentation of head and neck organs of interest.","authors":"Joëlle E van Aalst, Rita Simões, Federica C Maruccio, Daniel C MacRae, Luuk van der Hoek, Johannes A Langendijk, Peter M A van Ooijen, Tomas M Janssen, Charlotte L Brouwer","doi":"10.1016/j.radonc.2026.111826","DOIUrl":"https://doi.org/10.1016/j.radonc.2026.111826","url":null,"abstract":"<p><strong>Purpose: </strong>Quality assurance (QA) of auto-segmentations is necessary for safe clinical deployment. Deep learning models are optimised for data similar to their training set, but reliability drops with out-of-distribution (OOD) inputs. This study evaluates whether uncertainty quantification (UQ) can detect OOD inputs arising from distribution shift in head and neck organ of interest (OOI) auto-segmentation.</p><p><strong>Materials and methods: </strong>Monte Carlo dropout-based uncertainty scores and geometric accuracy of nnU-Net models were evaluated in two experiments. First, as a proof-of-concept, we assessed whether uncertainty scores detect metal artefact (N = 10) from non-artefact cases (N = 10) on a baseline model (mixed training data, N = 620) and a no-metal model (artefact-free training data, N = 620). Second, in a clinically realistic experiment, we split a fine-tuning dataset by uncertainty score to obtain a narrow model (low-uncertainty cases, N = 21) and a broad model (high-uncertainty cases, N = 21). A held-out test set (N = 76) evaluated whether segmentation accuracy differed between uncertainty categories.</p><p><strong>Results: </strong>Both experiments showed that uncertainty scores reflect the learned training distribution. In the supervised experiment, the no-metal model demonstrated greater uncertainty score separation between artefact and non-artefact cases (1.1 × 10⁵ vs 0.6 × 10⁵) than the baseline model (1.1 × 10⁵ vs 0.8 × 10⁵). In the unsupervised experiment, the narrow model performed significantly better on certain than uncertain cases (p = 0.04), while no difference was seen for the broad model (p = 0.34), which did include these cases in training.</p><p><strong>Conclusions: </strong>Uncertainty quantification can detect distribution shifts in radiotherapy auto-segmentation. This could support automated QA workflows by identifying in-distribution cases and enabling the application of specialised models.</p>","PeriodicalId":21041,"journal":{"name":"Radiotherapy and Oncology","volume":" ","pages":"111826"},"PeriodicalIF":5.8,"publicationDate":"2026-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149184173","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"From patient-reported outcome scores to clinical meaning: defining thresholds for clinical importance for the EORTC QLQ-PR25 questionnaire for patients with prostate cancer.","authors":"Samuel M Vorbach, Micha J Pilz, Maike Thumfart, Lionne D F Venderbos, Juan I Arraras, Renée Bultijnck, Ronita Mahilall, Esther Jimenez-Jimenez, Jörg-Andreas Müller, Heike Schmidt, Romaana Mir, Tara Chalk, John Ramage, Lisa Storz, Anna M M Thurner, Johannes M Giesinger","doi":"10.1016/j.radonc.2026.111817","DOIUrl":"10.1016/j.radonc.2026.111817","url":null,"abstract":"<p><strong>Background and purpose: </strong>Interpretation of patient-reported outcome scores remains challenging. Thresholds for clinical importance (TCIs) can facilitate score interpretation at the individual-patient level. We aimed to establish TCIs for the EORTC QLQ-PR25 to improve the interpretation of prostate cancer (PCa)-specific patient-reported outcomes in clinical practice and research.</p><p><strong>Methods: </strong>In this prospective multicentre study, 261 patients with PCa from seven countries completed the EORTC QLQ-PR25 and anchor items assessing limitations in daily life, need for help/care, and worries caused by the respective symptom or problem. Receiver operating characteristic analyses were used to derive TCIs for the QLQ-PR25 scales, using a binary criterion for clinical importance based on the anchor items. Sensitivity analyses explored threshold robustness across patient subgroups.</p><p><strong>Results: </strong>For five of the six QLQ-PR25 scales, ROC analyses showed acceptable to excellent discrimination, with AUC values ranging from 0.74 to 0.90. The corresponding TCIs showed sensitivity values between 0.62 and 0.88 and specificity values between 0.48 and 0.98. No meaningful threshold could be established for sexual activity (AUC = 0.48).</p><p><strong>Conclusions: </strong>This study provides the first TCIs for a questionnaire assessing health-related quality of life in patients with PCa. These thresholds may improve interpretation of individual patient scores, support symptom screening and clinical decision-making, and facilitate the definition of clinically meaningful outcomes in clinical research.</p>","PeriodicalId":21041,"journal":{"name":"Radiotherapy and Oncology","volume":" ","pages":"111817"},"PeriodicalIF":5.8,"publicationDate":"2026-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149166456","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dose-effect analysis of late dental adverse effects following radiation therapy in survivors of paediatric head and neck rhabdomyosarcoma.","authors":"Koen B Krommenhoek, Marinka L F Hol, Niels van der Aa, Michael Suttie, Mark N Gaze, Jan Wiersma, Henry C Mandeville, Callum Gillies, Olga Slater, Arjan Bel, Reinier C Hoogeveen, Johannes H M Merks, Daniel J Indelicato, Alfred G Becking","doi":"10.1016/j.radonc.2026.111820","DOIUrl":"10.1016/j.radonc.2026.111820","url":null,"abstract":"<p><strong>Introduction: </strong>Paediatric head and neck rhabdomyosarcomas (HNRMS) often require radiotherapy, causing dental complications during critical development. Limited literature suggests dose-dependent risks, but clear thresholds for late dental adverse effects are lacking. This study aims to characterize dose effects on developing dentition in paediatric HNRMS patients to identify dose-response relationships informing evidence-based treatment planning.</p><p><strong>Materials and methods: </strong>Orthopantomograms from survivors of HNRMS were evaluated using the validated DENTALE scoring system. Radiation doses from brachytherapy, external beam radiation with protons and photons to deciduous teeth were retrieved from treatment plans and converted to EQD2 (α/β = 3 Gy). Dose-response relationships were modelled per tooth using binary logistic regression in Mplus (COMPLEX option for within-patient dependency; model fit assessed by ROC analysis).</p><p><strong>Results: </strong>Among 34 survivors (median age at diagnosis 5.6 years), 27 (79.4 %) exhibited late dental AE. Of 919 assessable permanent teeth, 242 (26.3 %) showed abnormalities. Increasing radiation dose was consistently associated with higher AE probability. The dose corresponding to 50 % predicted probability of any dental AE was 23 Gy(EQD2). Structure-specific thresholds were higher for crowns (68 Gy) and eruption disturbances (52 Gy(EQD2)), and lower for roots (24 Gy(EQD2)) and crown-root ratio abnormalities (36 Gy(EQD2)).</p><p><strong>Conclusion: </strong>This study demonstrates dose-effect relationships for radiation exposure of developing dentition, with clinically relevant structure-specific thresholds. Teeth receiving no radiation still show developmental abnormalities, likely due to chemotherapy. These findings support incorporating dentition as organ at risk and dose constraints into paediatric head-and-neck radiotherapy planning to reduce dental morbidity.</p>","PeriodicalId":21041,"journal":{"name":"Radiotherapy and Oncology","volume":" ","pages":"111820"},"PeriodicalIF":5.8,"publicationDate":"2026-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149170350","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Regular post-treatment surveillance is associated with improved survival in nasopharyngeal carcinoma: a retrospective study.","authors":"Chen-Fei Wu, Qiu-Yi Pan, Yu-Xian Yang, Jia Kou, Yan-Fu Peng, Li-Lin, Jun Ma, Ying Sun, Jia-Wei Lv, Guan-Qun Zhou","doi":"10.1016/j.radonc.2026.111818","DOIUrl":"https://doi.org/10.1016/j.radonc.2026.111818","url":null,"abstract":"<p><strong>Purpose: </strong>Benefit of post-treatment surveillance in nasopharyngeal carcinoma (NPC), characterized by high recurrence risk, remains unexplored. We explored whether regular post-treatment surveillance facilitates earlier recurrence detection and improves survival.</p><p><strong>Methods and materials: </strong>We identified 8,798 patients with non-metastatic stage I-IVA NPC at Sun Yat-sen University Cancer Center. The 1-year landmark analysis was chosen as representative of surveillance patterns, dividing patients into regular and irregular surveillance group based on surveillance intensity. Cox proportional hazards models clarified the association between overall survival (OS) and surveillance intensity, with subgroup analyses stratified by clinical stage and pretreatment Epstein-Barr virus DNA level. Survival impact of surveillance imaging for local, regional, and distant sites were also investigated.</p><p><strong>Results: </strong>Median follow-up was 64.8 months. 1-year landmark analysis comprised 4,078 and 4,720 patients receiving regular (≥ 4 visits in the first year) and irregular surveillance (< 4 visits), respectively. Regular surveillance was linked to shorter median recurrence time (26.1 versus 27.0 months) and improved OS (HR, 0.86; 95% CI, 0.74-0.99; P = 0.032) after multivariable adjustment. Notably, patients receiving regular imaging surveillance for distant site had better OS (HR, 0.69; 95% CI, 0.57-0.82; P < 0.001) whereas imaging for local (HR, 1.36; 95% CI, 0.90-2.04; P = 0.140) and regional site (HR, 0.85; 95% CI, 0.57-1.27; P = 0.428) did not. Regular surveillance patients with distant metastases exhibited fewer metastatic organs (P < 0.001) and earlier recurrence stages (P < 0.001), translating into prolonged post-recurrence survival (HR, 0.68; 95% CI, 0.58-0.80; P < 0.001).</p><p><strong>Conclusions: </strong>Regular post-treatment surveillance, particularly distant imaging, could improve NPC survival, highlighting an urgency for evidence-based post-treatment surveillance strategies.</p>","PeriodicalId":21041,"journal":{"name":"Radiotherapy and Oncology","volume":" ","pages":"111818"},"PeriodicalIF":5.8,"publicationDate":"2026-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149166358","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ultra-hypofractionated versus conventional chemoradiation for newly diagnosed glioblastoma: Survival and toxicity results of a multicenter randomized trial.","authors":"Anouk M de Jong, Arthur T J van der Boog, Gerda Wester, Daniëlle B P Eekers, Tom C G Budiharto, Tom Rozema, Frank J Lagerwaard, Anna M E Bruynzeel, Crystal de Groot, Matthijs van der Meulen, Fia Cialdella, Jan-Willem Dankbaar, Jeroen Hendrikse, Karin E Kleynen, An Claes, Mariëlle E P Philippens, Ernst J Smid, Filip Y F L de Vos, Peter S N van Rossum, Pierre A Robe, Szabolcs David, Tom J Snijders, Joost J C Verhoeff","doi":"10.1016/j.radonc.2026.111726","DOIUrl":"10.1016/j.radonc.2026.111726","url":null,"abstract":"<p><strong>Purpose: </strong>In glioblastoma, standard first-line chemoradiation since the 2005 EORTC/NCIC trial is 30x2Gy with concurrent and adjuvant temozolomide. A phase II study suggested ultra-hypofractionation (6x6Gy) may offer comparable survival, with reduced treatment time and costs, potentially improving health-related quality of life (HRQoL). This phase III randomized trial (Netherlands Trial Registry, NL72953.041.20) evaluated non-inferiority of ultra-hypofractionated temozolomide chemoradiation in glioblastoma patients.</p><p><strong>Patients and methods: </strong>Adults with newly diagnosed glioblastoma and a Karnofsky performance status ≥70 were randomized (1:1) to ultra-hypofractionated (6x6Gy in 2 weeks) or standard (30x2Gy in 6 weeks) radiotherapy, both with concurrent and 6 cycles of adjuvant temozolomide. The primary endpoint was 2-year overall survival (OS); the non-inferiority margin was a hazard ratio of 1.2. Secondary outcomes included progression-free survival (PFS) and toxicity.</p><p><strong>Results: </strong>Enrollment stopped early, due to slow accrual (n=135/474 planned, 67 experimental, 68 standard). Median OS was shorter in the experimental arm: 13.0 months (95% CI 10.3-15.7) versus 21.0 months (95% CI not estimable). In a time-dependent analysis, survival was similar in the first 6 months (HR 0.99, 95% CI 0.39-2.50), but mortality was higher thereafter (HR 2.54, 95% CI 1.57-4.09, p < 0.001). Radiation necrosis or pseudoprogression was more frequent after ultra-hypofractionation (47.8% vs 16.2%; HR 5.20, 95% CI 2.56-10.58), with increased dexamethasone use at 6-12 months. No grade 4-5 toxicities were observed.</p><p><strong>Conclusion: </strong>Non-inferiority of the 6x6 Gy chemoradiation regimen could not be demonstrated. This ultra-hypofractionated regimen was associated with inferior survival and increased radiation necrosis, and therefore should not replace standard chemoradiation.</p>","PeriodicalId":21041,"journal":{"name":"Radiotherapy and Oncology","volume":" ","pages":"111726"},"PeriodicalIF":5.8,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148698037","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Temporal heart dose variations during IMPT for esophageal cancer and the impact of an adaptation protocol.","authors":"Richard Canters, Vlad Badiu, Dominique Reijtenbagh, Esther Kneepkens, Gloria Vilches-Freixas, Maaike Berbee","doi":"10.1016/j.radonc.2026.111717","DOIUrl":"10.1016/j.radonc.2026.111717","url":null,"abstract":"<p><strong>Purpose: </strong>In intensity-modulated proton therapy (IMPT) for esophageal cancer, organ motion can cause deviations between planned and delivered dose. Owing to posterior beam arrangements, the heart is particularly vulnerable, as the distal fall-off frequently overlaps cardiac tissue. This study quantified heart dose changes during treatment, identified contributing anatomical factors, and evaluated a heart-dose-guided adaptation protocol.</p><p><strong>Methods: </strong>We retrospectively analyzed 194 esophageal cancer patients treated with IMPT using weekly repeat CT scans (reCTs). Prescriptions were 23 × 1.8 Gy or 28 × 1.8 Gy (RBE). Plans were recalculated on each reCT to derive mean heart dose (MHD) and heart V40Gy. Dose trends were assessed alongside anatomical changes, including diaphragm baseline shift, heart position and volume, heart displacement, internal target volume (ITV), intraesophageal air, posterior subcutaneous adipose tissue, and dysphagia scores. Significant variables were included in an Elastic Net model to predict MHD changes with 10-fold cross-validation. The effect of an adaptation protocol-triggered by MHD increases >1.5 Gy or target underdosage-was evaluated in 111 patients treated after August 2022, 25 of whom underwent replanning due to increasing MHD.</p><p><strong>Results: </strong>Linear mixed modeling in all reCTs of 194 patients showed significant increases in MHD (0.4 Gy/week, p < 0.001) and heart V40Gy (4.1 cc/week, p < 0.001), alongside increased dysphagia scores, cranio-caudal heart displacement, reduced ITV, and diaphragm baseline shifts relative to planning CTs. Elastic Net modeling identified diaphragm shift and heart volume change as key predictors of MHD increase. In the full cohort, MHD increased by 0.7 Gy, while in the sub group of 25 adapted patients, the MHD increase was reduced from 1.5 Gy to 0.8 Gy (p < 0.01).</p><p><strong>Conclusion: </strong>Heart dose increases significantly during IMPT for esophageal cancer due to anatomical changes. Heart-dose-guided adaptive replanning effectively mitigates this increase.</p>","PeriodicalId":21041,"journal":{"name":"Radiotherapy and Oncology","volume":" ","pages":"111717"},"PeriodicalIF":5.8,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148702067","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Stereotactic ablative radiotherapy for oligometastatic breast cancer: A systematic review and meta-analysis (SABRINA).","authors":"Gustavo A Viani, Ana Carolina Hamamura, Caio Viani Arruda, Carlos E Cardoso, Helio A Salmon, Gustavo O Amaral","doi":"10.1016/j.radonc.2026.111789","DOIUrl":"https://doi.org/10.1016/j.radonc.2026.111789","url":null,"abstract":"<p><strong>Objective: </strong>Stereotactic ablative radiotherapy (SABR) is increasingly used for oligometastatic breast cancer, but it is unclear in whom local ablation translates into systemic benefit. We compared de novo oligometastatic (OM) with oligoprogressive (OP) disease and synthesised randomised evidence.</p><p><strong>Materials and methods: </strong>PubMed, EMBASE, Cochrane CENTRAL and ClinicalTrials.gov were searched through March 2026. Endpoints were local control (LC), progression-free survival (PFS), overall survival (OS), time to next systemic therapy (TTNS) and grade 3 or higher adverse events. Proportions were pooled by random-effects models, adverse events by a binomial-normal model accommodating zero-event studies, and trials separately.</p><p><strong>Results: </strong>Twenty-five cohorts (1,577 patients; 2,211 lesions) were included. Pooled LC was 92.5 % (95 % CI 90.4-94.2) at one year and 84.6 % (81.1-87.6) at two years, with no association with BED₁₀. At two years, PFS was 43.1 % (34.4-52.2) and OS 85.8 % (76.0-92.0). Outcomes were consistently superior in de novo OM than in OP: LC 95.7 % versus 88.9 % (p = 0.001), PFS 50.9 % versus 30.9 % (p = 0.003), OS 91.0 % versus 65.8 % (p = 0.002), and TTNS 18.5 versus 11.3 months. Within OP, lesion number was independently associated with TTNS (adjusted HR 1.77 per lesion). Across four randomised trials the pooled hazard ratio for PFS was 0.73 (0.53-1.00; p = 0.053). Grade 3 or higher adverse events occurred in 21 of 1,366 patients (1.50 %; 0.74-2.28).</p><p><strong>Conclusions: </strong>SABR achieves durable local control with few treatment-related adverse events in all clinical contexts. Clinical context, rather than dose or metastatic site, determines whether that local effect translates into systemic benefit. Randomised evidence neither establishes nor excludes a benefit; trials stratified by oligometastatic state are required.</p>","PeriodicalId":21041,"journal":{"name":"Radiotherapy and Oncology","volume":" ","pages":"111789"},"PeriodicalIF":5.8,"publicationDate":"2026-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149012373","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comment on \"Machine learning model for predicting interfraction motion of the seminal vesicles in prostate cancer radiotherapy\".","authors":"Appa Rao Nagubandi, Vijaya Rama Raju Gottimukkala, Sneha Singireddy","doi":"10.1016/j.radonc.2026.111616","DOIUrl":"10.1016/j.radonc.2026.111616","url":null,"abstract":"","PeriodicalId":21041,"journal":{"name":"Radiotherapy and Oncology","volume":" ","pages":"111616"},"PeriodicalIF":5.8,"publicationDate":"2026-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148199819","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to Comment on \"Machine learning model for predicting interfraction motion of the seminal vesicles in prostate cancer radiotherapy\".","authors":"Mitsuaki Terabe, Takeshi Kamomae, Yuki Taniguchi, Takayuki Miyachi, Hajime Ichikawa, Risei Miyauchi, Junji Ito, Mariko Kawamura, Shunichi Ishihara, Shinji Naganawa","doi":"10.1016/j.radonc.2026.111618","DOIUrl":"10.1016/j.radonc.2026.111618","url":null,"abstract":"","PeriodicalId":21041,"journal":{"name":"Radiotherapy and Oncology","volume":" ","pages":"111618"},"PeriodicalIF":5.3,"publicationDate":"2026-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148176271","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}